Fig. 5: CT7001 administration prevents CRPC growth in vivo and has additive effects in combination with enzalutamide.

a Tumour volumes on day 21 for male NSG mice bearing C4-2B xenografts following daily oral treatment with vehicle, CT7001 (50 mg/kg), enzalutamide (25 mg/kg) or combination (n = 10 per group). b Resected tumour weights at the end of 21 days of treatment. c Mean tumour volumes ± SEM over the course of treatment. Linear regression showed statistically significant differences in growth between different treatment groups. d Tumour doubling times ± 95% confidence intervals. e Plasma free prostate-specific antigen (PSA) levels in treated mice. f Mean change in body weight ± SEM of treated mice over the course of 21 days of treatment. g Quantification of immunohistochemistry (representative images in Supplemental Fig. 5D) staining in n = 3 animals per group (mean ± SEM). p values were determined using one-way ANOVA followed by Šídák’s multiple comparisons test. Data in a, b, e are presented using Tukey boxplots. Mean values are plotted as a “+” and outliers are shown as individual data points. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.